on the HUNT for the Next DIAMOND in the ROUGH
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"The fundamental progress the Company has made since our First Annual CEO Letter was released in May has been quite significant. We have achieved the following milestones:
Positive animal proof-of concept data for MANF in the multi-billion dollar Myocardial Infarction market;.....( heart disease )
Secured the license for the NuroPro Parkinson's diagnostic blood test; and...
Successfully concluded our research collaboration with Banyan Biomarkers, showing positive proof-of concept data for MANF in Traumatic Brain Injury.
$AMBS "THE CURE-MAKER"with 1000's of studies over the years from independent researchers of Manf and AMARANTUS having a patent on it until 2031 ....even before it is FDA approved it is worth 30 times what the Market Cap. is now and they own many other patents too. The co. has spent over 30 MILLION in research already from a report I read a couple weeks ago.
LOL....your welcome
HEART DISEASE positive research data
http://ih.advfn.com/p.php?pid=nmona&article=54308207
Most exciting thing is MANF is potential cure for many diseases that kill.....not just Parkinson's.....but Amarantus has to concentrate on one at a time until new partners are acquired
he's definitely got the experience and the "connections" working for a BIG BIO like Brystol.....wait until he gets the word out
I think AMARANTUS should let these guys know who owns patent to the REAL CURE not something that stops working after 7 years
http://www.marketwire.com/press-release/medgenesis-announces-new-grant-for-the-development-of-gdnf-1711187.htm
Clinton says
"I am very excited to join Amarantus at this critical time in its growth cycle," said Clinton O. Allen, newly appointed advisor to Amarantus. "The team at Amarantus has been working tremendously hard over the last few years to bring the MANF Program closer to actualizing its true potential. Now that the Company is looking at various partnering and funding opportunities to drive shareholder value, it is an opportune time to join the team in order meticulously evaluate proposals and make recommendations for future growth."
Clinton Allen Bristol Myers Squibb
http://ih.advfn.com/p.php?pid=nmona&article=54616032
AM I the only one here seeing in $1.00's and not just cents
Am I at the Right time at the Right Place
All it takes is the Right partner
$AMBS
Does everyone know that we have on board the Director of Product Development and Commercialization, of a 55 BILLION $ market Cap. Company
$AMBS
what is the substania nigra
http://www.wisegeek.com/what-is-the-substantia-nigra.htm
$AMBS
I see everyone had an exciting day today....and welcome to all the new posters
didn't do too well in English reading did you
Manf is supposed to reverse the cells dying...I wonder how long and often one would have to take it?
and how many cures do they have?
“Translational research includes two areas of translation. One is the process of applying discoveries generated during research in the laboratory, and in preclinical studies, to the development of trials and studies in humans. The second area of translation concerns research aimed at enhancing the adoption of best practices in the community.”
I guess their scientists/researchers know what they are doing over there
On 17 October 2012, Amarantus BioSciences, Inc. was awarded a Translational Research Grant award from the University of Massachusetts' Pioneer Valley Life Sciences Institute's Center of Excellence in Apoptosis Research (CEAR).
Four of the world’s top biotechs are in New England
http://www.masshightech.com/stories/2012/08/27/daily33-Four-of-the-worlds-top-biotechs-are-in-New-England.html
Myocardial infarction (MI) or acute myocardial infarction (AMI), commonly known as a heart attack
The body has a built-in system to get rid of old, damaged, or unnecessary cells. Called apoptosis, this "programmed cell death" is critical to good health. If the system stops working, abnormal cells accumulate, which can cause diseases such as cancer. If the system works too well, an abundance of healthy cells are destroyed, causing severe tissue damage that can lead to Parkinson's disease, Alzheimer's disease, diabetes, and other neurodegenerative disorders. The Center of Excellence in Apoptosis Research (CEAR) was created in 2006 to support research into this critical system-and what happens when it malfunctions.
The University of Massachusetts Amherst is well-known for its breadth of research expertise in apoptosis, or programmed cell death. This important biological process is known to play a significant role in a wide range of devastating health problems, including cancer, neurodegenerative disorders, type 1 diabetes, and reperfusion injuries following heart attacks and strokes.
With funding from the Massachusetts Technology Collaborative's John Adams Innovation Institute, we launched the Center of Excellence in Apoptosis Research (CEAR) in 2006. Located at PVLSI, the center crosses disciplines to create research groups that focus on signaling pathways that regulate apoptosis. The teams then use their findings to develop new diagnostic tools and therapies to treat human disease.
Everyone have an exciting day tomorrow
or is that why it has taken almost ten years to get to this point
This is all to Good to Be true so it must not be true
In July 2010, the company received a notice of allowance for Composition of Matter patents for MANF throughout Europe. In
January 2012, the company was awarded a US Patent protecting composition of matter for MANF. Amarantus has filed additional
patent claims domestically and abroad: Method of use patent in US, EU, Japan, Canada, China, India, and Brazil; PCT
Neurodegenerative disorders method of use patent application.
I guess it is a Drug but I often link side effects to most drugs taken....I Don't think there could be side effects to taking a protein which the body already produces....
In pharmacology, a drug is "a chemical substance used in the treatment, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well-being."[3] Drugs may be prescribed for a limited duration, or on a regular basis for chronic disorders.[4]
Animal and human studies confirm that MANF is a
biological protein that is produced in the body to establish and maintain the nervous system. Furthermore,
studies have shown that MANF is also highly produced during times of cardiac stress, indicating that this
protein plays a crucial role in heart health.
Over 1.5 million people suffer from Parkinson’s disease in the United States, Western
Europe, and Japan alone. The NIH estimates at least 500,000 people in the United States suffer from PD,
and the total cost to the nation exceeds $6B annually. The company has stated the incidence of PD is likely
to double in the next 20 years due to increase in average lifespan, coupled with a larger population
approaching retirement. In 2009, the PD market generated $2.2B across the seven major markets. Between
2005 and 2009, the dopamine agonist class dominated the market, accounting for nearly half of PD market
sales. Additionally, newer catechol-O-methyltransferase inhibitor and monoamine oxidase inhibitor classes
have continued to penetrate the market. It is predicted that generic incursion in these classes will limit the
market share, and a continued unimpressive late-stage pipeline with unproven benefits and differentiation
will open the door for a new first-in-class opportunity.
I can see a buyout of this co. by a big guy just to put this technology in their back pocket.....Billions of $$$ will be lost by other companies who currently "TREAT" many central nervous system diseases with DRUGS
Am I wrong?
MANF is a
biological protein that is produced in the body to establish and maintain the nervous system
NOT A DRUG
MANF (AMRS001) was discovered studying Amarantus’ first established cell line of neurons. It was found to
have a striking ability to save neurons from cell death when disease conditions were presented. This was a
remarkable finding in regard to therapeutic potential, as neuron cell death is the underlying cause of
neurologic conditions such as Parkinson’s disease. Animal and human studies confirm that MANF is a
biological protein that is produced in the body to establish and maintain the nervous system. Furthermore,
studies have shown that MANF is also highly produced during times of cardiac stress, indicating that this
protein plays a crucial role in heart health.
MANF is not a drug.....so no side effects?
The Company also owns an inventory of 88 cell lines referred to as “PhenoGuard Cell Lines.”
MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company’s inventory of PhenoGuard Cell Lines.
and Parkinson's is just the Tip of the Iceberg
There are numerous other uses for their patented MANF. I believe it will be a GAME CHANGER in the whole Biotech Sector
all the pieces of the puzzle starting to fall into place. Company is preparing for major success
A director should consider owning shares of the Company’s common stock having a dollar value of at least five times the value of the then-applicable annual retainer paid for service on the Board. Ownership is measured annually as of December 31 of each calendar year, based on the average closing price of a share of Amarantus stock as traded on the New York Stock Exchange for the last 30 trading days of the year.
http://www.amarantus.com/wp-content/uploads/2012/10/Amarantus-Biosciences-Corporate-Governance-Guidelines.pdf
This is only the beginning this is heading for Much Higher Ground
CEO compared company and their patents to others being bought for 30 Million plus in the past.
you should never take the advice of buying or selling from a message board but I can advise you that this is one stock to spend some time doing your D.D. on----you should then make your own decision as to invest or not. I have made my decision a few weeks ago and I have no regrets.....the potential here is HUGE
and that was in their research phase where start up Biotech need the money the most.....Now they are in the developmental stage and thats where we come in---- to invest in a proven technology that will bring Enormous returns on our investment
10,500 followers of Company on twitter
https://twitter.com/AmarantusBio
once this starts heading North....we may very well see that gap filled quick